Hepatoprotective and hypolipidaemic effects of glycoprotein isolated from Gardenia jasminoides ellis in mice.
The present study was performed to investigate the hepatoprotective and hypolipidaemic effects of a 27 kDa glycoprotein isolated from Gardenia jasminoides Ellis (GJE glycoprotein) in glucose/glucose oxidase (G/GO)-treated BNL CL.2 cells, as well as in CCl4, Triton WR-1339 and corn oil-treated mice. In G/GO-treated BNL CL.2 cells, the results showed that GJE glycoprotein has an inhibitory effect on G/GO-induced cytotoxicity and intracellular reactive oxygen species production. In addition, GJE glycoprotein has an anti-oxidant effect against the lipid peroxidation process in the Fe2+/ascorbic acid system. In CCl4 (1.0 mL/kg)-treated mice, pretreatment with GJE glycoprotein (80 mg/kg) blocked lactate dehydrogenase release and the formation of thiobarbituric acid-reactive substances. In addition, in these mice GJE resulted in increased nitric oxide production and the activation of anti-oxidant enzymes, accompanied by the inhibition of the cytotoxic-related signals hepatic cytochrome c, nuclear factor-kappaB and activator protein-1. In both Triton WR-1339 (400 mg/kg) and corn oil (1.0 g/kg)-treated mice, pretreatment with GJE glycoprotein (80 mg/kg) lowered the levels of plasma lipoproteins (triglyceride, total cholesterol and low-density lipoprotein). On the basis of these results, we assume that GJE glycoprotein can ameliorate liver function, because it has hepatoprotective and hypolipidaemic activities.
Lee
Sei-Jung
SJ
Molecular Biochemistry Laboratory, Institute of Biotechnology, Chonnam National University, Kwangju, South Korea.
Oh
Phil-Sun
PS
Lim
Kye-Taek
KT
D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D002251:Carbon Tetrachloride / Q000633:toxicity; D003314:Corn Oil / Q000009:adverse effects; D045304:Cytochromes c / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D032062:Gardenia / Q000737:chemistry*; D006023:Glycoproteins / Q000302:isolation & purification* / Q000494:pharmacology*; D006949:Hyperlipidemias / Q000139:chemically induced; D000960:Hypolipidemic Agents / Q000302:isolation & purification / Q000494:pharmacology; D007770:L-Lactate Dehydrogenase / Q000097:blood; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D016328:NF-kappa B / Q000378:metabolism; D009569:Nitric Oxide / Q000097:blood; D011092:Polyethylene Glycols / Q000009:adverse effects; D017382:Reactive Oxygen Species / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D018808:Transcription Factor AP-1 / Q000378:metabolism
D000975:Antioxidants; D006023:Glycoproteins; D000960:Hypolipidemic Agents; D016328:NF-kappa B; D017382:Reactive Oxygen Species; D017392:Thiobarbituric Acid Reactive Substances; D018808:Transcription Factor AP-1; D009569:Nitric Oxide; D011092:Polyethylene Glycols; D003314:Corn Oil; D045304:Cytochromes c; D002251:Carbon Tetrachloride; D007770:L-Lactate Dehydrogenase; C016811:tyloxapol